Fig. 1.

Ka treatment alleviates motor dysfunction and increases dopamine levels in the striatum of MPTP/p PD model mice.

(a) Schematic diagram of the experimental design.(b) Time on the rod was measured for the rotarod test on three consecutive days. (c–d) The time taken to turn around (time of turning) and descend a pole (time of climbing) were recorded for the pole test. (e) Mouse body weights were measured at the end of the study. (f–g) Dopamine (DA) and dihydroxy-phenyl acetic acid (DOPAC) in the striatum were analyzed by high-performance liquid chromatography. The data are expressed as the mean ± SEM. n = 9–10 for each group in (b, c, d); n = 6–8 for each group in (f, g). ns, not significant, *P < 0.05, **P < 0.01, ***P < 0.001, by one-way ANOVA followed by Tukey's post hoc test. MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Ka, kaempferol.